StockNow
Calendar
Log in
U.S. Markets

Gilead Sciences (GILD) entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited; deal valued at USD 1.27bln in upfront cash

StockNow breaking-news AI analysis

Gilead reportedly agreed to acquire PepStar’s oral IL-23R inhibitor program, including HCXT-2001, for USD 1.27 billion upfront; no further terms or timeline were found.

News detail

Deal expected to reduce GAAP and non-gaap EPS by USD 0.79-0.83 in Q4 2026.

1 stocks
GILDGilead Sciences Inc$157.32Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US President Trump says "Iran is doing everything they can to drive up the price of Oil prior to the U.S. Midterm Election".

Fed

Money markets no longer fully price a Fed rate hike before end of 2026

Geopolitics

US President Trump says regarding Iran that they have crushed the Islamic Republic and may want to do it a little bit more